Search - tctmd.com

Displaying 1 - 20 of 45

Sort: Relevancy | Date

News Conference News ACC 2026

Despite Guidelines, Aspirin Is Used in Fewer Than One in Four High-risk Pregnancies

Yael L. Maxwell

April 03, 2026

News Conference News ACC 2026

PCSK9 Inhibitor Very Effective in High-risk Patients Without ASCVD: VESALIUS-CV

Michael O'Riordan

March 29, 2026

News Conference News ACC 2026

Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE

Yael L. Maxwell

March 28, 2026

News Conference News ACC 2026

KARDINAL: Monthly Tonlamarsen May Not Enhance BP Lowering in Resistant Hypertension

Caitlin E. Cox

March 28, 2026

News Conference News ACC 2026

What’s Going to Be Hot at ACC 2026

Michael O'Riordan

March 20, 2026

News Conference News ACC 2025

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

L.A. McKeown

April 10, 2025

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

Presentation ACC 2025

STRIDE - Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes

Presenter: Marc P. Bonaca

March 29, 2025

Presentation ACC 2025

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

Presenter: Darren K. McGuire

March 29, 2025

News Daily News ACC 2025

STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients

L.A. McKeown

March 29, 2025

News Conference News ACC 2024

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Michael O'Riordan

April 12, 2024

News Conference News ACC 2024

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

Todd Neale

March 27, 2024

News Conference News ACC 2023

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

Michael O'Riordan

March 14, 2023

News Conference News ACC 2023

CRP More Predictive of Future Events Than LDL in Statin-Treated Patients

Caitlin E. Cox

March 14, 2023

News Conference News ACC 2023

Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR

Michael O'Riordan

March 13, 2023

News Conference News ACC 2023

Multifaceted Approach to COORDINATE Diabetes Care Improves GDMT

Yael L. Maxwell

March 07, 2023

Presentation ACC 2023

A Cluster-Randomized Trial to Improve Care of Patients in Cardiology Clinics with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease [COORDINATE-Diabetes]

Presenter: Neha J. Pagidipati

March 05, 2023

News Conference News ACC 2023

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Michael O'Riordan

March 04, 2023

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Shelley Wood

April 01, 2022

News Conference News ACC 2021

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

Michael O'Riordan

May 25, 2021

Advertisement

Despite Guidelines, Aspirin Is Used in Fewer Than One in Four High-risk Pregnancies

PCSK9 Inhibitor Very Effective in High-risk Patients Without ASCVD: VESALIUS-CV

Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE

KARDINAL: Monthly Tonlamarsen May Not Enhance BP Lowering in Resistant Hypertension

What’s Going to Be Hot at ACC 2026

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

STRIDE - Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

CRP More Predictive of Future Events Than LDL in Statin-Treated Patients

Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR

Multifaceted Approach to COORDINATE Diabetes Care Improves GDMT

A Cluster-Randomized Trial to Improve Care of Patients in Cardiology Clinics with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease [COORDINATE-Diabetes]

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content